From Seekingalpha · · 30s
TL;DR: AbCellera Presents at UBS Biopharma Conference
AbCellera CEO shares antibody tech advances at UBS Global Biopharma Conference 2026.
AbCellera's CEO highlights antibody platform progress targeting GPCRs and ion channels at UBS conference. AbCellera CEO shares antibody tech advances at UBS Global Biopharma Conference 2026. Carl L. Hansen, CEO, President & Chairperson of AbCellera Biologics Inc. (ABCL) presented at UBS Global Biopharma Conference 2026. AbCellera's 14-year platform targets GPCRs, ion channels, and T-cell engagers with best-in-world technology.
- AbCellera CEO
- Antibody Platform Focus
- Biotech Business Model
Read the story version — the same reporting as a swipeable deck of 3 cards.
